Humacyte (NASDAQ: HUMA) — Perfil da empresa, notícias e dados financeiros
Humacyte is a biotechnology firm focused on developing human acellular vessels for medical applications.
Humacyte
Humacyte (NASDAQ:HUMA) is a biotechnology firm focused on developing and manufacturing human acellular vessels (HAVs) for various medical applications, including vascular and emergency trauma surgery. The company's flagship project, HAV, aims to revolutionize regenerative medicine by providing a bioengineered alternative to synthetic grafts and donor tissues. With a commitment to improving patient outcomes and advancing the field of regenerative medicine, Humacyte's objectives include clinical research, product innovation, and expanding the application of its technologies to address a broad range of medical conditions.
Resumo
Operações
Produtos e/ou serviços de Humacyte
- Human Acellular Vessels (HAVs) for vascular replacement and reconstruction, offering a bioengineered alternative for patients needing arterial or venous repairs.
- Regenerative medicine solutions targeting the repair or replacement of damaged human tissue and organs, leveraging bioengineered tissues.
- R&D collaborations with military and defense agencies to develop advanced treatments for trauma and battlefield injuries.
- Bioengineered tracheal implants designed for patients with tracheal defects, stenosis, or tracheal injuries, improving airway reconstruction techniques.
- Development of bioengineered urethral constructs aiming to provide solutions for complex urethral stricture diseases.
- Investigations into bioengineered human tissue applications for cardiovascular diseases, focusing on potential treatments for heart attacks and heart disease.
equipe executiva do Humacyte
- Laura E. NiklasonFounder, President, CEO & Director
- Dale A. SanderCFO, Chief Corporate Development Officer & Treasurer
- Shamik J. ParikhChief Medical Officer
- Sabrina OsborneChief People Officer
- Lisa MolyneuxChief Strategy Officer
- Heather ConnellyChief Quality & Regulatory Officer
- Rick McElhenySenior Vice President of Business Development
- Jim MercadanteChief Commercial Officer
- Todd E. RasmussenChief Surgical Officer
Principais indicadores financeiros
Resultados divulgados pela Humacyte, em USD.
- Cap. de mercado
- 124 mi
- Receita (TTM)
- 2,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 2 mi | -107,4 mi | -40,8 mi | |
| 0 | -114,4 mi | -148,7 mi | |
| 0 | -100 mi | -110,8 mi | |
| 1,6 mi | -84,6 mi | -12 mi |